Abstract: Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising: a substrate layer; an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid; a protective film which can be removed at the moment of use.

Abstract: Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising: a substrate layer; an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid; a protective film which can be removed at the moment of use.

Abstract: Cicatrizant hydrocolloidal patch comprising:

Abstract: Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising:

Abstract: Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising: a substrate layer; an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid; a protective film which can be removed at the moment of use.

Abstract: Cicatrizant hydrocolloidal patch comprising:

Abstract: Thin adhesive plaster having a thickness lower than 500 &mgr;m for the treatment of psoriasis, dermatitis and dermatosis, comprising: a) a support comprising an outer layer in plastic film and an inner layer in woven or non-woven fabric having approximately the same size as the plastic film, b) an adhesive layer placed on the support inner layer having approximately the same size as the support comprising an adhesive matrix in the form of hydrogel, betamethasone or a pharmaceutically acceptable salt thereof and optionally hyaluronic acid or a pharmaceutically acceptable salt thereof, c) a protective plastic film contacted with the adhesive layer and removable immediately prior to use.

Abstract: A new process, particularly simple and economical, for FSH and LH separation and purification starting from crude HMG preferably urinary, comprising the following steps:1) optional exhaustion of crude HMG viral charge in aqueous EtOH2) ion-exchange chromatography on weakly basic anionic resins of DEAE type;3) affinity chromatography on resin having an antraquinone derivative as a ligand;4) optional ion-exchange chromatography on strongly basic anionic resins;Hormones obtained thereby, in particularly pure form and having high specific activity, may subsequently undergo a depyrogenation step.

Abstract: The salts, in the crystalline form, of ibuprofen and naproxen with N-(2-hydroxyethyl) pyrrolidine are prepared by dissolving ibuprofen and naproxen respectively in a suitable organic solvent, by adding N-(2-hydroxyethyl) pyrrolidine, by letting the compounds react, by removing the solvent and by crystallizing the obtained salt from a solution in an apolar and aprotic solvent.Said salts have a high solubility in water and are used for preparing pharmaceutic compositions for oral and other administrations.